The Residual Risk Reduction Initiative

Your login
Your password
Confirm your password
Your email
I agree to receive the R3i newsletter
Yes No

Prof. Henry Ginsberg

Columbia University,
New York, USA


Current position

1994 -	Irving Professor of Medicine at Columbia University College of Physicians and Surgeons, New York, NY, USA
2006 -	Associate Dean for Clinical and Translational Research and Director of the Irving Institute for Clinical and Translational Research at Columbia University Medical Center in New York, NY, USA

Past position

1978 - 1985	Assistant Professor at the Mount Sinai School of Medicine, New York, NY, USA
1993 - 2001	Head, Division of Preventive Medicine and Nutrution, Columbia University College of Physicians and Surgeons, New York, NY, USA
1994 - 2006	Director General Clinical Research Center, Columbia University College of Physicians and Surgeons, New York, NY, USA

Scientific training

	MD at the State University of New York Downstate Medical Center in Brooklyn, NY, USA Training in internal medicine in the Boston University Service of the Boston City Hospital, Boston, MA, USA Training in endocrinology and metabolism at Stanford University, Palo Alto, CA, USA

Professional Associations

	Member of the American Diabetes Association
	Fellow of the AHA Council on Arteriosclerosis, Thrombosis and Vascular Biology
	Fellow of the AHA Council on Nutrition, Physical Activity and Metabolism
	Fellow of the American Association for the Advancement of Science
	Member of the American Society for Clinical Investigation
	Member of the Association of American Physicians
	Member of the editorial boards of The Journal of Clinical Investigation, Journal of Lipid Research, and Journal of Metabolism

Publications (recent)
Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol. 2008 Apr 1;101(7):1003-8. Reyes G, Yasunaga K, Rothenstein E, Karmally W, Ramakrishnan R, Holleran S, Ginsberg HN. Effects of a 1,3-diacylglycerol oil-enriched diet on postprandial lipemia in people with insulin resistance. J Lipid Res. 2008 Mar;49(3):670-8 Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alemán JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 2008 Feb;7(2):125-34 Ota T, Gayet C, Ginsberg HN. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest. 2008 Jan;118(1):316-32 Berglund L, Lefevre M, Ginsberg HN, Kris-Etherton PM, Elmer PJ, Stewart PW, Ershow A, Pearson TA, Dennis BH, Roheim PS, Ramakrishnan R, Reed R, Stewart K, Phillips KM; DELTA Investigators. Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. Am J Clin Nutr. 2007 Dec;86(6):1611-20 Saito S, Hernandez-Ono A, Ginsberg HN. Dietary 1,3-diacylglycerol protects against diet-induced obesity and insulin resistance. Metabolism. 2007 Nov;56(11):1566-75. Saland JM, Ginsberg HN. Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol. 2007 Aug;22(8):1095-112 Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007 Jul;29(7):1354-67 Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, O'connor PJ, Leiter LA, Weiss D, Lipkin E, Fleg JL; ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007 Jun 18;99(12A):56i-67i Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG; ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007 Jun 18;99(12A):4i-20i

Research

	Principal Investigator of one of the first 12 NIH–funded Clinical Translational Science Awards (CTSA) Principal investigator on two R01 research grants from the NIH, National Heart, Lung, and Blood Institute Co-principal investigator at Columbia on the ACCORD Trial

His research interests have focused on the regulation of plasma cholesterol and triglyceride blood levels, particularly the metabolism of apolipoprotein B–containing lipoproteins in cells, mice, and humans. Much of his present work focuses on the interaction between insulin resistance and increased secretion of very low-density lipoproteins by the liver. Very active in clinical research training and education, Dr. Ginsberg was also program director of a T32 Postdoctoral Training Grant in Arteriosclerosis for the past 15 years. The CTSA includes a predoctoral T32 program in translational research, a master’s degree program in patient oriented research, and a junior faculty K12 Clinical Research Scholars Program.